Dashboard
Manage Tickers

ACRV


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
11/03/2025 12:05:47

acrivon-therapeutics-to-deliver-three-presentations-at-the-aacr-nci-eortc-highlighting-advances-from-its-proprietary-generative-phosphoproteomics-ap3-platform-for-developing-precision-medicines
Acrivon Therapeutics To Deliver Three Pres...
10/22/2025 20:29:30

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 12:09:28

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/08/2025 17:07:17

why-robinhood-shares-are-trading-higher-by-over-7-here-are-20-stocks-moving-premarket
Why Robinhood Shares Are Trading Higher By...
09/08/2025 09:30:18

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
09/05/2025 21:06:11

oppenheimer-maintains-outperform-on-acrivon-therapeutics-lowers-price-target-to-8
Oppenheimer Maintains Outperform on Acrivo...
08/14/2025 18:08:01

Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price targ...

acrivon-therapeutics-q2-eps-055-beats-058-estimate
Acrivon Therapeutics Q2 EPS $(0.55) Beats ...
08/13/2025 20:17:35

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of ...

jones-trading-downgrades-acrivon-therapeutics-to-hold
Jones Trading Downgrades Acrivon Therapeut...
05/16/2025 20:33:51

Jones Trading analyst Soumit Roy downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Hold.

acrivon-therapeutics-q1-eps-051-beats-066-estimate
Acrivon Therapeutics Q1 EPS $(0.51) Beats ...
05/14/2025 20:28:13

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of ...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/01/2025 12:05:58

acrivon-therapeutics-announces-it-will-present-data-from-ap3-generative-phosphoproteomic-analyses-of-acr-2316-regulated-cdk1--cdk2--and-plk1-induced-pathways-at--a-american-association-for-cancer-research-annual-meeting-april-25-30-2025-in-chicago-illinois
Acrivon Therapeutics Announces It Will Pre...
04/25/2025 12:09:47

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tum...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/16/2025 17:06:28

hc-wainwright--co-reiterates-buy-on-acrivon-therapeutics-maintains-19-price-target
HC Wainwright & Co. Reiterates Buy on Acri...
03/28/2025 10:43:18

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 pric...

acrivon-therapeutics-says-cash-runway-extended-into-2027
Acrivon Therapeutics Says Cash Runway Exte...
03/27/2025 21:47:20

acrivon-therapeutics-q4-2024-gaap-eps-060-beats-066-estimate
Acrivon Therapeutics Q4 2024 GAAP EPS $(0....
03/27/2025 21:46:03

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
03/26/2025 21:05:44

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
03/26/2025 17:05:38

cantor-fitzgerald-reiterates-overweight-on-acrivon-therapeuticsto-overweight
Cantor Fitzgerald Reiterates Overweight on...
03/26/2025 14:11:10

Cantor Fitzgerald analyst Li Watsek reiterates Acrivon Therapeutics (NASDAQ:ACRV) from Overweight to Overweight.

citizens-capital-markets-reiterates-market-outperform-on-acrivon-therapeutics-maintains-17-price-target
Citizens Capital Markets Reiterates Market...
03/26/2025 12:59:59

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION